ArticleNPJ biofilms and microbiomes2023
Metaproteogenomic analysis of saliva samples from Parkinson's disease patients with cognitive impairment.
Article in NPJ biofilms and microbiomes, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Association between oral dysbiosis and Parkinson's disease: a systematic review.Frontiers in cellular and infection microbiology · 2025Pooled it
- Oral Microbiota Associated With Parkinson'S Disease: A Systematic Review.Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric DentistryPooled it
- Advances in Oral Cavity Stem Cell Research Revealed through Multi-omics Analysis.Stem cell reviews and reports · 2026Review
- Dysregulation of Oral Microbial Eicosapentaenoic Acid Induced by Chronic Restraint Stress Exacerbates Periodontitis via M1 Macrophage Polarization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Oral health and oral microbiota composition in patients with Parkinson's disease: a case‒control study.Journal of oral microbiology · 2026Article
- Microbiome signatures of virulence in the oral-gut-brain axis influence Parkinson's disease and cognitive decline pathophysiology.Gut microbes · 2025Article
- Integrated multi-omics highlights alterations of gut microbiome functions in prodromal and idiopathic Parkinson's disease.Microbiome · 2025Article
- The microbiologist's guide to metaproteomics.iMeta · 2025Review
- A multi-omics integration approach relying on circulating factors does not discern subtypes of childhood type 1 diabetes.Communications medicine · 2025Article
- OSaMPle workflow for salivary metaproteomics analysis reveals dysbiosis in inflammatory bowel disease patients.NPJ biofilms and microbiomes · 2025Article
- Oral microbiota and central nervous system diseases: A review.Neuroprotection (Chichester, England) · 2025Review
- Oral and gut microbiome profiles in people with early idiopathic Parkinson's disease.Communications medicine · 2024Article
- Microbiota Orchestra in Parkinson's Disease: The Nasal and Oral Maestros.Biomedicines · 2024Review
- Comprehensive analysis of the oral microbiota and metabolome change in patients of burning mouth syndrome with psychiatric symptoms.Journal of oral microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 3 countries.
Funding
Abstract
Cognitive impairment (CI) is very common in patients with Parkinson's Disease (PD) and progressively develops on a spectrum from mild cognitive impairment (PD-MCI) to full dementia (PDD). Identification of PD patients at risk of developing cognitive decline, therefore, is unmet need in the clinic to manage the disease. Previous studies reported that oral microbiota of PD patients was altered even at early stages and poor oral hygiene is associated with dementia. However, data from single modalities are often unable to explain complex chronic diseases in the brain and cannot reliably predict the risk of disease progression. Here, we performed integrative metaproteogenomic characterization of salivary microbiota and tested the hypothesis that biological molecules of saliva and saliva microbiota dynamically shift in association with the progression of cognitive decline and harbor discriminatory key signatures across the spectrum of CI in PD. We recruited a cohort of 115 participants in a multi-center study and employed multi-omics factor analysis (MOFA) to integrate amplicon sequencing and metaproteomic analysis to identify signature taxa and proteins in saliva. Our baseline analyses revealed contrasting interplay between the genus Neisseria and Lactobacillus and Ligilactobacillus genera across the spectrum of CI. The group specific signature profiles enabled us to identify bacterial genera and protein groups associated with CI stages in PD. Our study describes compositional dynamics of saliva across the spectrum of CI in PD and paves the way for developing non-invasive biomarker strategies to predict the risk of CI progression in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.